ArticleOncoimmunology
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.Genes · 2022Pooled it
- Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.Journal of ovarian research · 2026Article
- Oncolytic measles virotherapy encoding the neutrophil-activating protein is effective in synovial sarcoma.Molecular therapy. Oncology · 2025Article
- Transcriptomic-Based Classification Identifies Prognostic Subtypes and Therapeutic Strategies in Soft Tissue Sarcomas.Cancers · 2025Article
- Immunological differences between monophasic and biphasic synovial sarcoma with implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2024Article
- Genetic and Molecular Heterogeneity of Synovial Sarcoma and Associated Challenges in Therapy.Cells · 2024Review
- Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges.European journal of cancer (Oxford, England : 1990) · 2023Review
- Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma.Cancers · 2023Review
- A library of cancer testis specific T cell receptors for T cell receptor gene therapy.Molecular therapy oncolytics · 2023Article
- Treatment at Relapse for Synovial Sarcoma of Children, Adolescents and Young Adults: From the State of Art to Future Clinical Perspectives.Cancer management and research · 2023Review
- PRAME Immuno-Expression in Cutaneous Sebaceous Carcinoma: A Single Institutional Experience.Journal of clinical medicine · 2022Article
- Review
- Article
- Article
- Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?Biomedicines · 2021Review
- Targeting cancer testis antigens in synovial sarcoma.Journal for immunotherapy of cancer · 2021Review
- RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Is immunotherapy in the future of therapeutic management of sarcomas?Journal of translational medicine · 2021Review
- Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?Cancers · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synovial sarcoma expresses multiple cancer testis antigens that could potentially be targeted by T-cell receptor (TCR) gene therapy. In this study we investigated whether PRAME-TCR-gene therapy could be an effective treatment for synovial sarcoma by investigating the potential of PRAME-specific T-cells to recognize sarcoma cells and by evaluating the expression patterns of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.